PIPELINE
PIPELINE
PIPELINE
Pipeline | Status | R&D Plan | Potential Indications | |
TRTP-101 | Phase 1 Completed | - Continued development of atrophic scar therapy - Expansion of indications for dermal-related unmet needs - Expansion of indications in other areas using and improving data such as *CMC(chemistry, manufacturing and control) of TRTP-101 | - Atrophic scar - Wounds - Burn - Wrinkle - Decubitus ulcer - Hair loss | |
TRTP-102 | Injectable osteoarthritis therapy (regenerative medicine) | Osteoarthritis, meniscus damage | ||
TRTP-103 | Ligament and Tendon regenerative medicine | Frozen shoulder | ||
TRTP-104 | Plastic surgery | Hair loss | ||
TRTP-20X | Pre-clinical | Severe cartilage defects / osteoarthritis organoid regenerative medicine | - Severe cartilage defects - Osteoarthritis | |
TRTP-30X | MoA, CMC | - Pure human organoid-derived extracellular matrix - Exosome | Medical materials (materials such as medical devices and cosmetics) | |
TRTP-40X | MoA, CMC | Angiogenetic organoid product | - Buerger's disease - Diabetic ulcer / diabetes mellitus wound | |
TRTP-50X | MoA, CMC | Organoid technology-based muscle therapy | - Sarcopenia - Charcot-Marie-Tooth | |
TRTP-90X | Cell Bank Technology | - Stem cell / organoid cell bank technology - Cryopreservation technology | ||
* CMC : Chemistry, Manufacturing, Control
* ECM : Extracellular Matrix
Pipeline
Pipeline | Status | R&D Plan | Potential Indications | |
TRTP-101 | Phase 1 Completed | - Continued development of atrophic scar therapy - Expansion of indications for dermal-related unmet needs - Expansion of indications in other areas using and improving data such as *CMC(chemistry, manufacturing and control) of TRTP-101 | - Atrophic scar - Wounds - Burn - Wrinkle - Decubitus ulcer - Hair loss | |
TRTP-102 | Injectable osteoarthritis therapy (regenerative medicine) | Osteoarthritis, meniscus damage | ||
TRTP-103 | Ligament and Tendon regenerative medicine | Frozen shoulder | ||
TRTP-104 | Plastic surgery | Hair loss | ||
TRTP-20X | Pre-clinical | Severe cartilage defects / osteoarthritis organoid regenerative medicine | - Severe cartilage defects - Osteoarthritis | |
TRTP-30X | MoA, CMC | - Pure human organoid-derived extracellular matrix - Exosome | Medical materials (materials such as medical devices and cosmetics) | |
TRTP-40X | MoA, CMC | Angiogenetic organoid product | - Buerger's disease - Diabetic ulcer / diabetes mellitus wound | |
TRTP-50X | MoA, CMC | Organoid technology-based muscle therapy | - Sarcopenia - Charcot-Marie-Tooth | |
TRTP-90X | Cell Bank Technology | - Stem cell / organoid cell bank technology - Cryopreservation technology | ||
* CMC : Chemistry, Manufacturing, Control
* ECM : Extracellular Matrix
2nd Floor, Room 203, 240-39 Changgyeonggung-ro, Jongno-gu, Seoul, South Korea (Gwangwon Building, Myeongnyun 4-ga)
TEL +82-2-742-0032 FAX +82-2-764-7300
Room 501, Biomaterials Research Building, 101 Daehak-ro, Jongno-gu, Seoul, South Korea (Seoul National University School of Dentistry)
TEL +82-2-740-8641 FAX +82-2-742-8666
Room 523, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea (Teratower, Munjeong Station)
TEL +82-2-742-0032 FAX +82-2-764-7300
Rooms 513–515, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea (Teratower, Munjeong Station)
TEL +82-2-742-0032 FAX +82-2-764-7300
2nd Floor, Room 203, 240-39 Changgyeonggung-ro, Jongno-gu, Seoul, South Korea (Gwangwon Building, Myeongnyun 4-ga)
TEL +82-2-742-0032
FAX +82-2-764-7300
Room 501, Biomaterials Research Building, 101 Daehak-ro, Jongno-gu, Seoul, South Korea
(Seoul National University School of Dentistry)
TEL +82-2-740-8641
FAX +82-2-742-8666
Room 523, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea
(Teratower, Munjeong Station)
TEL +82-2-742-0032
FAX +82-2-764-7300
Rooms 513–515, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea
(Teratower, Munjeong Station)
TEL +82-2-742-0032
FAX +82-2-764-7300
office@cellincells.com
Copyrights © 2025 CELLinCELLS co.,Ltd. All Rights Reserved.